JPWO2022221276A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022221276A5
JPWO2022221276A5 JP2023562714A JP2023562714A JPWO2022221276A5 JP WO2022221276 A5 JPWO2022221276 A5 JP WO2022221276A5 JP 2023562714 A JP2023562714 A JP 2023562714A JP 2023562714 A JP2023562714 A JP 2023562714A JP WO2022221276 A5 JPWO2022221276 A5 JP WO2022221276A5
Authority
JP
Japan
Prior art keywords
sequence
seq
mirna
aav
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515612A (ja
JP2024515612A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024415 external-priority patent/WO2022221276A1/en
Publication of JP2024515612A publication Critical patent/JP2024515612A/ja
Publication of JPWO2022221276A5 publication Critical patent/JPWO2022221276A5/ja
Publication of JP2024515612A5 publication Critical patent/JP2024515612A5/ja
Pending legal-status Critical Current

Links

JP2023562714A 2021-04-12 2022-04-12 球脊髄性筋萎縮症(sbma)の治療に有用な組成物 Pending JP2024515612A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173885P 2021-04-12 2021-04-12
US63/173,885 2021-04-12
US202163187883P 2021-05-12 2021-05-12
US63/187,883 2021-05-12
US202163293505P 2021-12-23 2021-12-23
US63/293,505 2021-12-23
PCT/US2022/024415 WO2022221276A1 (en) 2021-04-12 2022-04-12 Compositions useful for treating spinal and bulbar muscular atrophy (sbma)

Publications (3)

Publication Number Publication Date
JP2024515612A JP2024515612A (ja) 2024-04-10
JPWO2022221276A5 true JPWO2022221276A5 (https=) 2025-04-21
JP2024515612A5 JP2024515612A5 (https=) 2025-04-21

Family

ID=81748336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562714A Pending JP2024515612A (ja) 2021-04-12 2022-04-12 球脊髄性筋萎縮症(sbma)の治療に有用な組成物

Country Status (10)

Country Link
US (1) US20240191258A1 (https=)
EP (1) EP4323520A1 (https=)
JP (1) JP2024515612A (https=)
KR (1) KR20230170022A (https=)
AU (1) AU2022258312A1 (https=)
BR (1) BR112023021245A2 (https=)
CA (1) CA3215141A1 (https=)
IL (1) IL307633A (https=)
MX (1) MX2023012052A (https=)
WO (1) WO2022221276A1 (https=)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
JP5872162B2 (ja) * 2007-11-26 2016-03-01 エンゾン ファーマシューティカルズ,インコーポレーテッド アンドロゲン受容体を標的化するlnaアンタゴニスト
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
CA3052487A1 (en) * 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JOP20190200A1 (ar) * 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018168961A1 (ja) 2017-03-16 2018-09-20 株式会社デンソー 自己位置推定装置
MX2020008932A (es) 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
IL276859B2 (en) 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
TW202045728A (zh) * 2019-02-26 2020-12-16 賓州大學委員會 用於治療克拉培氏病之組成物
BR112021021908A2 (pt) * 2019-05-03 2022-02-01 Univ Pennsylvania Composições úteis no tratamento da leucodistrofia metacromática
GB201912863D0 (en) * 2019-09-06 2019-10-23 Babraham Inst Novel method

Similar Documents

Publication Publication Date Title
EP3947653A1 (en) Peptide-modified hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism and increased muscle transduction
JP2020537543A (ja) ライソゾーム病の遺伝子治療
JP7106534B2 (ja) メチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
US20250041453A1 (en) Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
EP4536686B1 (en) Peptide-modified aav capsid with enhanced muscle transduction efficiency
US20250041452A1 (en) Methods and compositions for treating mybpc3 related hypertrophic cardiomyopathy with a viral vector
US20250195694A1 (en) Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
US20250205365A1 (en) Methods and compositions for treating rbm20 related cardiomyopathy with a viral vector
JPWO2020172490A5 (https=)
JP2020510433A5 (https=)
JPWO2022221276A5 (https=)
US20250195695A1 (en) Methods and compositions for treating tmem43 related cardiomyopathy with a viral vector
CA3240197A1 (en) Compositions comprising kozak sequences selected for enhanced expression
US20240350663A1 (en) Isolated modified aav9 capsid protein vp1
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのaqp1遺伝子療法
US20220136005A1 (en) One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation
US20240024512A1 (en) Methods and compositions for treating tecpr2-associated disease and disorders with a viral vector
Gregorevic et al. Functional enhancement of skeletal muscle by gene transfer
Transgene 290. A Rationally Engineered Novel Capsid Variant of AAV9 for Peripheral Tissue-Detargeted and CNS-Directed Systemic Gene Delivery
Meliani et al. 311. AAV8 Vexosome Vectors Enhance Cell Transduction In Vitro and Outperform Conventional AAV8 Vectors in Liver-Transduction In Vivo in the Presence of Anti-AAV Neutralizing Antibodies